12th Street Asset Management Company LLC Acquires Shares of 91,123 Harrow, Inc. $HROW

12th Street Asset Management Company LLC acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the fourth quarter, HoldingsChannel reports. The fund acquired 91,123 shares of the company’s stock, valued at approximately $4,465,000.

A number of other institutional investors also recently made changes to their positions in HROW. Raymond James Financial Inc. bought a new stake in shares of Harrow in the second quarter worth $48,000. SBI Securities Co. Ltd. grew its holdings in Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after acquiring an additional 846 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after purchasing an additional 2,615 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Harrow by 848.2% in the 3rd quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock valued at $104,000 after purchasing an additional 1,934 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $33.00 on Tuesday. The company has a market cap of $1.23 billion, a PE ratio of -80.49 and a beta of 0.34. Harrow, Inc. has a fifty-two week low of $25.21 and a fifty-two week high of $54.85. The firm has a 50-day simple moving average of $36.02 and a 200 day simple moving average of $41.95. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The company had revenue of $44.20 million for the quarter, compared to the consensus estimate of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period last year, the company posted ($0.38) earnings per share. On average, sell-side analysts anticipate that Harrow, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on HROW. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research report on Friday, April 3rd. Weiss Ratings cut Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Nomura downgraded Harrow to a “neutral” rating in a report on Wednesday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Harrow in a research report on Thursday, March 19th. Finally, Cantor Fitzgerald lowered their price target on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.43.

Insider Buying and Selling

In related news, CFO Andrew R. Boll acquired 3,500 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average cost of $29.90 per share, for a total transaction of $104,650.00. Following the purchase, the chief financial officer directly owned 814,679 shares in the company, valued at $24,358,902.10. This represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Adrienne L. Graves bought 1,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was bought at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $31,070. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.80% of the company’s stock.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.